Efficacy of intranasal administration of a modified live feline herpesvirus 1 and feline calicivirus vaccine against disease caused by Bordetella bronchiseptica after experimental challenge

Detection of Mycoplasma spp. and feline calicivirus in cats with ocular surface disease

OBJECTIVE

To survey the prevalence of pathogens in shelter-housed cats with active ocular surface disease (OSD).

ANIMALS STUDIED

A total of 255 shelter-housed domestic cats with evidence of active OSD. No normal, unaffected cats were sampled.

PROCEDURE(S)

OSD scoring was performed on cats with active OSD. Combined oropharyngeal/conjunctival swabs were submitted for rt-PCR/PCR for feline herpesvirus (FHV-1), feline calicivirus (FCV), Chlamydia spp. (CHL), Bordetella bronchiseptica (BORD), and Mycoplasma spp. (MYC).

RESULTS

Pathogens were detected as follows: 76.4% (195/255) MYC, 57.6% (147/255) FHV-1, 42.7% (109/255) FCV, 26.7% (68/255) CHL, and 5.5% (14/255) BORD. Monoinfections affected 21.1% (54/255) animals, with MYC being the most common monoinfection (12.5%, 32/255), followed by FHV-1 (4.7%, 12/255), followed by CHL (2.4%, 6/255), followed by FCV (1.6%, 4/255), with no animals having a BORD monoinfection. Dual infections affected 36.4% of animals (93/255), with MYC detected in 30.1% (77/255) dual infections and FCV detected in 12.9% (33/255) dual infections. Dual infections with MYC and FCV together were detected in 9.8% (25/255) animals. Many animals (35.3%, 90/255) were found to be affected by 3 or more pathogens, and 7.1% (18/255) animals had no pathogens detected. OSD scores were not influenced by any variable assessed, including the number and type of pathogens detected.

CONCLUSION

MYC, FHV-1, FCV, and CHL were commonly detected in this group of animals with OSD. Both MYC and FCV (alone or in combination with each other) were detected in multiple animals with active OSD, supporting prior evidence that either may independently act as a primary ocular surface pathogen.

A portable centrifugal genetic analyzer for multiplex detection of feline upper respiratory tract disease pathogens

We present a portable genetic analyzer with an integrated centrifugal disc which is equipped with a glass-filter extraction column for purifying nucleic acid (NA) and multiple reaction chambers for analyzing major feline upper respiratory tract disease (FURTD) pathogens. We targeted four kinds of FURTD including Feline herpesvirus 1 (FHV), Mycoplasma felis (MPF), Bordetella bronchiseptica (BDB), and Chlamydophila felis (CDF). The portable genetic analyzer consists of a spinning motor, two pairs of Peltier heaters, two Minco heater, fluorescent optics, a touchscreen, and software for data analysis, so loop-mediated isothermal amplification (LAMP) or polymerase chain reaction (PCR) can be performed. The overall size of the genetic analyzer was 28 cm × 28 cm × 26 cm and the weight was 10 kg, which was deliverable for point-of-care testing (POCT). Owing to the sophisticated microchannel design and spinning program, the serial injection of the sample solution, the washing solution, and the elution solution was executed through a glass filter membrane for nucleic acid (NA) extraction, and then the cocktail with the purified genome was aliquoted into 9 reaction chambers for LAMP or PCR. The whole process for the LAMP reaction or the PCR was completed within 1.5 h. The fluorescence profiles by a scanning mode showed the matched results between the LAMP and the PCR.

Use of feline herpesvirus as a vaccine vector offers alternative applications for feline health

Herpesviruses are attractive vaccine vector candidates due to their large double stranded DNA genome and latency characteristics. Within the scope of veterinary vaccines, herpesvirus-vectored vaccines have been well studied and commercially available vectored vaccines are used to help prevent diseases in different animal species. Felid alphaherpesvirus 1 (FHV-1) has been characterised as a vector candidate to protect against a range of feline pathogens. In this review we highlight the methods used to construct FHV-1 based vaccines and their outcomes, while also proposing alternative uses for FHV-1 as a viral vector.

Feline vaccines

Many of the decisions regarding the vaccination of cats relate to the animal’s lifestyle. Vaccination requirements for the solitary indoor cat are very different than those for feral or free-roaming cats. Core vaccines include those directed against feline herpesvirus, feline parvovirus, and feline caliciviruses. Other important vaccines include the mandated rabies vaccination and also vaccination against feline leukemia. One significant issue with respect to feline vaccination is the development of injection site sarcomas. Although the prevalence of these is low and should not inhibit the use of vaccines, they are impossible to predict and very difficult to treat.

2020 AAHA/AAFP Feline Vaccination Guidelines

The guidelines are a consensus report on current recommendations for vaccination of cats of any origin, authored by a Task Force of experts. The guidelines are published simultaneously in the Journal of Feline Medicine and Surgery (volume 22, issue 9, pages 813-830, DOI: 10.1177/1098612X20941784) and the Journal of the American Animal Hospital Association (volume 56, issue 4, pages 249-265, DOI: 10.5326/JAAHA-MS-7123). The guidelines assign approved feline vaccines to core (recommended for all cats) and non-core (recommended based on an individualized risk-benefit assessment) categories. Practitioners can develop individualized vaccination protocols consisting of core vaccines and non-core vaccines based on exposure and susceptibility risk as defined by the patient's life stage, lifestyle, and place of origin and by environmental and epidemiologic factors. An update on feline injection-site sarcomas indicates that occurrence of this sequela remains infrequent and idiosyncratic. Staff education initiatives should enable the veterinary practice team to be proficient in advising clients on proper vaccination practices and compliance. Vaccination is a component of a preventive healthcare plan. The vaccination visit should always include a thorough physical exam and client education dialog that gives the pet owner an understanding of how clinical staff assess disease risk and propose recommendations that help ensure an enduring owner-pet relationship.

2020 AAHA/AAFP Feline Vaccination Guidelines*

The guidelines are a consensus report on current recommendations for vaccination of cats of any origin, authored by a Task Force of experts. The guidelines are published simultaneously in the Journal of Feline Medicine and Surgery (volume 22, issue 9, pages 813–830, DOI: 10.1177/1098612X20941784) and the Journal of the American Animal Hospital Association (volume 56, issue 4, pages 249–265, DOI: 10.5326/JAAHA-MS-7123). The guidelines assign approved feline vaccines to core (recommended for all cats) and non-core (recommended based on an individualized risk-benefit assessment) categories. Practitioners can develop individualized vaccination protocols consisting of core vaccines and non-core vaccines based on exposure and susceptibility risk as defined by the patient’s life stage, lifestyle, and place of origin and by environmental and epidemiologic factors. An update on feline injection-site sarcomas indicates that occurrence of this sequela remains infrequent and idiosyncratic. Staff education initiatives should enable the veterinary practice team to be proficient in advising clients on proper vaccination practices and compliance. Vaccination is a component of a preventive healthcare plan. The vaccination visit should always include a thorough physical exam and client education dialog that gives the pet owner an understanding of how clinical staff assess disease risk and propose recommendations that help ensure an enduring owner-pet relationship.

Prevention of respiratory infections with alpha- and gamma-herpesviruses in weanling foals by using a modified live intra-nasal equine influenza vaccine

This study aimed to determine if the administration of a modified live equine influenza virus vaccine (FluAvert) to foals would positively impact their health and reduce colonization of their upper airways with equine herpesviruses (EHV) during the weaning period. A single dose of FluAvert was given to 20 healthy foals 7 days prior to being weaned; 20 healthy foals served as unvaccinated controls. Nasal secretions and blood were collected before vaccination, the day of weaning, and weekly thereafter for 3 weeks. Nasal secretions were tested by quantitative polymerase chain reaction (qPCR) for EHV-1, -2, -4 and -5. Whole blood was analyzed for a complete blood cell count and fibrinogen concentration. Physical assessments were made daily. The use of FluAvert was associated with a better clinical outcome. However, the equine influenza virus (EIV) vaccine did not influence selected hematological parameters and kinetics of herpesviruses. The clinical benefit observed in vaccinates may explain the perception that the EIV vaccine induces cross-protection against respiratory agents.

Evaluation of liposome toll-like receptor ligand complexes for non-specific mucosal immunoprotection from feline herpesvirus-1 infection

Background

Feline herpesvirus‐1 (FHV‐1) infection can result in serious morbidity and mortality, especially in kittens. Immunotherapy using liposome‐toll‐like receptor (TLR) ligand complexes (LTC) has been shown to activate innate immune responses.

Objectives

To determine in kittens whether mucosal administration of LTC before FHV‐1 inoculation would decrease severity of clinical signs and decrease quantities of FHV‐1 DNA in materials collected on oropharyngeal swabs.

Animals

Nineteen, 14‐week‐old, purpose‐bred kittens.

Methods

Pilot clinical trial with 2 groups of kittens allocated to either an LTC or control group. The LTC were administered into both nares and the oropharynx of the 12 LTC group kittens, and all 19 kittens were inoculated with FHV‐1 24 hours later. Clinical scores were determined daily for 28 days, and oropharyngeal mucosal materials were collected every 7 days to assess FHV‐1 DNA quantities for comparison between groups.

Results

Conjunctivitis was more common in kittens in the control group on Days 15‐28 (P = .01) and Days 1‐28 (P = .02). Total respiratory scores were higher in the LTC group on days 15‐28 (P = .03). The LTC group had significantly decreased FHV‐1 DNA on swabs when compared to the control group on some postinoculation days, using 2 methods of calculation.

Conclusions and Clinical Importance

Administration of LTC to kittens was shown to decrease FHV‐1 DNA and some manifestations of illness in kittens when administrated 24 hours before inoculation, suggesting clinical benefit.

Activation of upper respiratory tract mucosal innate immune responses in cats by liposomal toll-like receptor ligand complexes delivered topically

BACKGROUND

Nonspecific induction of local innate immune responses by mucosally administered immunotherapy is a new approach to protection from upper respiratory tract infections. Therefore, a new liposome-toll-like receptor complex (LTC) immune stimulant was developed and investigated for its ability to activate innate immune responses in cats, both in vitro and in vivo, as part of an initial evaluation of LTC for use as an immunotherapeutic agent in cats.

OBJECTIVES

We hypothesized that LTC could activate innate immune responses in cats after topical application to nasal and oropharyngeal mucosal surfaces.

ANIMALS

Mucosal immune responses to topical administration of LTC were assessed in 7 healthy, purpose-bred cats, and in vitro responses were assessed using blood samples from healthy cats.

METHODS

Cytokine and cellular immune responses to LTC were evaluated in blood samples, nasal lavage specimens, and pharyngeal swabs from cats, using reverse transcriptase polymerase chain reaction assays, ELISA assays, and flow cytometry.

RESULTS

Liposome-TLR complexes rapidly activated leukocytes in vitro, including upregulation of costimulatory molecule expression and cytokine production. Topical administration of LTC in healthy cats triggered rapid recruitment of monocytes to the nasal and oropharyngeal mucosa.

CONCLUSIONS AND CLINICAL IMPORTANCE

Liposome-TLR complexes were found to effectively activate innate immune responses in cats after mucosal administration. These findings suggest that LTC have potential for use as a new mucosally administered immunotherapy for nonspecific protection from viral and bacterial respiratory tract infections.

Another Look at the "Dismal Science" and Jenner's Experiment

The follow-up to Jenner's experiment, routine vaccination, has reduced more disease and saved more vertebrate lives than any other iatrogenic procedure by orders of magnitude. The unassailability of that potentially provocative cliché has been ciphered in human medicine, even if it is more difficult in our profession. Most public relations headaches concerning vaccines are a failure to communicate, often resulting in overly great expectations. Even in the throes of a tight appointment schedule remembering and synopsizing (for clients), some details of the dismal science can make practice great again.

The First Siphoviridae Family Bacteriophages Infecting Bordetella bronchiseptica Isolated from Environment

Bordetella bronchiseptica is a well-known etiological agent of kennel cough in dogs and cats and one of the two causative agents of atrophic rhinitis, a serious swine disease. The aim of the study was to isolate B. bronchiseptica bacteriophages from environmental samples for the first time. A total of 29 phages from 65 water samples were isolated using the strain ATCC 10580 as a host. The lytic spectra of the phages were examined at 25 and 37 °C, using 12 strains of B. bronchiseptica. All phages were able to plaque on 25.0 % to 41.7 % of the strains. The selected phages showed similar morphology (Siphoviridae, morphotype B2), but variation of RFLP patterns and efficacy of plating on various strains. The partial genome sequence of phage vB_BbrS_CN1 showed its similarity to phages from genus Yuavirus. Using PCR, it was confirmed that the phages do not originate from the host strain, and environmental origin was additionally confirmed by the analysis of host genome sequence in silico and plating heated and unheated samples in parallel. Accordingly, this is the first isolation of B. bronchiseptica phages from environment and the first isolation and characterization of phages of B. bronchiseptica belonging to family Siphoviridae.

Evaluation of a modified Karnofsky score to assess physical and psychological wellbeing of cats in a hospital setting

Objectives The Karnofsky score (KS) modified for cats, a scoring system to rate health and quality of life (QOL) in cats, is used in clinical trials, but its reliability and validity are yet to be determined. The present study aims to evaluate the scientific robustness of the KS when adapted for use in a hospital setting. Methods A list of variables to consider during the physical examination, which informs the clinician's score (CS) part of the KS, was added and clinicians were allowed to choose a score anywhere between 0 and 50. The Karnofsky QOL questionnaire was adapted for use in a hospital setting. F-tests with Bonferroni correction and Spearman rank correlation coefficients were used to evaluate reliability and validity of the KS to assess the health and wellbeing of cats in a hospital setting. The records of 54 feline immunodeficiency virus-positive cats, which were recruited for a clinical trial and hospitalised for 6 weeks, were reviewed. Four veterinarians scored the CS, and one veterinarian and a veterinary nurse assessed the QOL score. Results Mean absolute difference between observers was significantly larger for the CS than for the QOL score ( P <0.001) and two veterinarians scored significantly higher than the remaining two veterinarians ( P <0.001). Inter-observer correlation ranged from 0.45-0.75 for the CS. For the QOL score, the absolute difference between observers was small, no significant difference was found between observers and a high degree of inter-observer correlation was noted (r = 0.91). Conclusions and relevance The results indicate low inter-observer reliability for the CS, requiring additional modifications to this part of the KS. The QOL score seems more reliable, and the questionnaire may serve as a reliable tool in the assessment of QOL in cats in a hospital setting. Consequently, further adaptation of the KS is mandatory when simultaneous assessment of both the cat's clinical health and perceived wellbeing is required.

Evaluation of intranasal vaccine administration and high-dose interferon- α2b therapy for treatment of chronic upper respiratory tract infections in shelter cats

Clinical signs of upper respiratory tract infection can be hard to manage in cats, particularly those in shelters. In this study, clinical data were collected from chronically ill (3-4 weeks' duration) cats with suspected feline herpesvirus-1 (FHV-1) or feline calicivirus (FCV) infections after administration of one of two novel therapies. Group A cats were administered a commercially available formulation of human interferon-α2b at 10,000 U/kg subcutaneously for 14 days, and group B cats were administered one dose of a FHV-1 and FCV intranasal vaccine. Molecular assays for FHV-1 and FCV were performed on pharyngeal samples, and a number of cytokines were measured in the blood of some cats. A clinical score was determined daily for 14 days, with cats that developed an acceptable response by day 14 returning to the shelter for adoption. Those failing the first treatment protocol were entered into the alternate treatment group. During the first treatment period, 8/13 cats in group A (61.5%) and all 12 cats in group B (100%) had apparent responses. The seven cats positive for nucleic acids of FHV-1 or FCV responded favorably, independent of the treatment group. There were no differences in cytokine levels between cats that responded to therapy or failed therapy. Either protocol assessed here may be beneficial in alleviating chronic clinical signs of suspected feline viral upper respiratory tract disease in some cats that have failed other, more conventional, therapies. The results of this study warrant additional research involving these protocols.

Comparative efficacy of intranasal and oral vaccines against Bordetella bronchiseptica in dogs

In order to determine the comparative efficacy of vaccines administered intranasally or orally to protect puppies from disease subsequent to experimental infection with Bordetella bronchiseptica (Bb), a randomized controlled trial was performed using 48 approximately 8-week-old specific pathogen free, Bb naive Beagle puppies. Puppies were randomized into three groups and administered vaccines containing Bb intranasally or orally, or a placebo intranasally. Twenty-one days later, all dogs were challenge exposed via aerosol administration of Bb. Clinical signs, nasal bacterial shedding and immune responses were monitored for 28 days after challenge. Intranasally vaccinated puppies had significantly lower rates of coughing, nasal discharge, retching and sneezing (i.e. were less sick clinically) than control puppies. The distinction between the orally vaccinated puppies and the control puppies was less consistent. The orally vaccinated puppies had less coughing and less retching than the control puppies, but nasal discharge and sneezing did not differ from control animals. Orally vaccinated puppies had higher rates of coughing, nasal discharge, retching and sneezing than the intranasally vaccinated puppies. Although both intranasal and oral Bb vaccines stimulated immune responses associated with disease sparing following Bb infection, the intranasal route of delivery conferred superior clinical outcomes. The observed difference in clinical efficacy suggests the need to question the rationale for the use of currently available orally administered Bb vaccines.

How well do vaccines for Bordetella bronchiseptica work in dogs? A critical review of the literature 1977-2014

Bordetella bronchiseptica (Bb) has long been causally associated with respiratory disease in dogs. Parenteral and intranasal vaccines for this pathogen have been in common use since their development in the late 1970s and early 1980s and recently a commercial oral Bb vaccine has become available. Overall, the literature (comprising experimental infection models and field studies) documents the efficacy of these vaccines in stimulating disease-sparing mucosal and systemic immune responses that can be associated with reduced growth of Bb in vivo. However, many of the published studies are limited by flaws in experimental design, most notably a failure to consider the biological and statistical implications of the 'pen effect'. Many questions related to the longevity of vaccine induced immunity against Bb and the impact of natural exposure on herd immunity remain unanswered.

Concurrent administration of an intranasal vaccine containing feline herpesvirus-1 (FHV-1) with a parenteral vaccine containing FHV-1 is superior to parenteral vaccination alone in an acute FHV-1 challenge model

The administration of intranasal (IN) or subcutaneous (SC) vaccines containing modified live feline herpesvirus 1 (FHV-1) offers some level of protection against FHV-1 challenge, but relative efficacy is <100%. In this study, clinical signs and viral shedding in kittens were compared among three groups: (1) kittens vaccinated concurrently with IN and SC vaccines containing FHV-1 (Group 1, n = 8); (2) kittens vaccinated with a SC FHV-1 vaccine alone (Group 2, n = 8), and (3) unvaccinated control kittens (Group 3, n = 8). All kittens were FHV-1 naïve at enrolment, and challenge with a virulent strain of FHV-1 was performed 1 week after vaccination. Daily clinical signs and pharyngeal FHV-1 shedding were recorded over a 21-day infection period. Overall, kittens in Group 1 had significantly less severe clinical illness than those in Group 2 (P < 0.05). Additionally, significantly less FHV-1 DNA was detected on pharyngeal swabs from kittens in Group 1 compared to those in Group 2 (P < 0.001). Concomitant administration of IN and SC FHV-1 vaccines was superior to administration of the SC FHV-1 vaccine alone in this challenge model of FHV-1 naïve kittens.

ABCD: Update of the 2009 guidelines on prevention and management of feline infectious diseases

OVERVIEW

In this article, the ABCD guidelines published in the JFMS Special Issue of July 2009 (Volume 11, Issue 7, pages 527-620) are updated by including previously unavailable and novel information. For a better picture, the reader is advised to consult that issue before focusing on the novel features.